CIK 0000818686
- Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 39148213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-03-04 | Dethlefs Sven EVP Global Marketing&Portfolio | Grant or award · Restricted Share Units | +41,791 | 41,791 | ||
| 2019-03-04 | de Notaristefani Carlo Executive VP Global Operations | Grant or award · Restricted Share Units | +74,626 | 74,626 | ||
| 2019-03-04 | Daniell Richard Exec. VP, European Commercial | Grant or award · Restricted Share Units | +47,761 | 47,761 | ||
| 2019-03-04 | Codner Iris Beck EVP Global Brand&Communication | Grant or award · Restricted Share Units | +26,865 | 26,865 | ||
| 2019-03-04 | Nazzi Gianfranco EVP, Growth Markets Commercial | Sale | −512 | $16.88 | $9K | 7,892.36 |
| 2019-03-04 | O'Grady Brendan P. EVP, North America Commercial | Sale | −1,166 | $16.88 | $20K | 1,388.49 |
| 2019-03-04 | McClellan Michael James EVP, Chief Financial Officer | Sale | −363 | $16.88 | $6K | 12,330.27 |
| 2019-03-04 | Griffin Deborah A Chief Accounting Officer | Sale | −2,941 | $16.88 | $50K | 1,166 |
| 2019-03-04 | Griffin Deborah A Chief Accounting Officer | Sale | −1,166 | $16.88 | $20K | 0 |
| 2019-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +1,165 | 16,502.51 | ||
| 2019-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −409 | $16.88 | $7K | 16,093.51 |
| 2019-03-04 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −1,165 | 0 | ||
| 2019-03-04 | Dethlefs Sven EVP Global Marketing&Portfolio | Sale | −606 | $16.88 | $10K | 8,057.7 |
| 2019-03-04 | Daniell Richard Exec. VP, European Commercial | Sale | −2,098 | $16.88 | $35K | 0 |
| 2019-03-03 | Nazzi Gianfranco EVP, Growth Markets Commercial | Option exercise | +1,399 | 8,404.36 | ||
| 2019-03-03 | Nazzi Gianfranco EVP, Growth Markets Commercial | Option exercise · Restricted Share Units | −1,399 | 2,799 | ||
| 2019-03-03 | O'Grady Brendan P. EVP, North America Commercial | Option exercise | +1,166 | 2,554.49 | ||
| 2019-03-03 | O'Grady Brendan P. EVP, North America Commercial | Option exercise · Restricted Share Units | −1,166 | 2,332 | ||
| 2019-03-03 | McClellan Michael James EVP, Chief Financial Officer | Option exercise | +1,049 | 12,693.27 | ||
| 2019-03-03 | McClellan Michael James EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −1,049 | 2,099 |
Page 67 of 76 · 1,517 trades